Gilead Sciences Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for GILD, updated each market day.
GILD AI Sentiment
AI sees no strong directional signal for Gilead Sciences Inc stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector
Exchange
Market Cap
$187,096,833,337
Cap Tier
Employees
17,000
Headquarters
FOSTER CITY, CA
Listed Since
Jan. 22, 1992
Website
GILD Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GILD Volatility
Gilead Sciences Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
